Company Encyclopedia
View More
name
BTBP
600161.SH
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.
1.579 T
600161.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking5/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.91%B
    • Profit Margin20.49%A
    • Gross Margin40.69%B
  • Growth ScoreB
    • Revenue YoY22.78%A
    • Net Profit YoY3.29%C
    • Total Assets YoY6.41%B
    • Net Assets YoY7.93%B
  • Cash ScoreB
    • Cash Flow Margin488.06%C
    • OCF YoY22.78%A
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreA
    • Gearing Ratio9.69%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BTBP: Reviewed the third quarterly report, adjusted the structure, and acquired 1% equity in Songzi Pulp Station

    BTBP announced that the 26th meeting of the 9th Board of Directors held on October 23, 2025, reviewed several proposals. First, it approved the "Q3 2025 Report"; second, it agreed to abolish the Blood Source Management Center and establish the Blood Source Management Department and Blood Source Management Region; third, it agreed that its subsidiary, TianTan Wuhan, would acquire 1% equity of Songzi Plasma Station for 222,660 yuan, after which it will hold 100% equity; fourth, it approved the proposal to authorize the general manager's office to make decisions on pre-approval matters related to economic activities

    Zhitong·
    SH
    600161
    +0.59%
    Zhitong·
    SH
    600161
    +0.59%

    BTBP: Recently officially launched Phase III clinical trials for human prothrombin complex

    BTBP announced that its subsidiary has officially launched the Phase III clinical trial of human prothrombin complex, which is used to treat various coagulation factor deficiencies. Although similar products are already available in domestic and international markets, this product still needs to complete clinical trials and market application, and investors should be aware of the associated risks

    Zhitong·
    SH
    600161
    +0.59%
    Zhitong·
    SH
    600161
    +0.59%

    BTBP: Tiantan Kunming has been approved to conduct clinical trials for "human fibrinogen"

    BTBP announced that its subsidiary TianTan Kunming has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen." This product must complete clinical trials, submit a market application, and pass relevant reviews and approval processes before it can be produced and sold on the market

    Zhitong·
    SH
    600161
    +0.59%
    Zhitong·
    SH
    600161
    +0.59%

    BTBP's subsidiary received a notice of compliance inspection for drug GMP

    According to the Zhitong Finance APP, BTBP announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as "Chengdu Rongsheng") has received the "Drug GMP Compliance Inspection Notification" issued by the Sichuan Provincial Drug Administration, involving the workshop for: recombinant product production workshop

    Zhitong·
    SH
    600161
    +0.59%
    Zhitong·
    SH
    600161
    +0.59%

    Beijing BTBP 2025 Half-Year Equity Distribution Implementation Announcement Released

    Beijing BTBP Biotechnology Co., Ltd. announced the implementation of the 2025 semi-annual equity distribution, deciding to distribute a cash dividend of RMB 0.15 per share, totaling RMB 296,605,716.90. The equity registration date is September 24, 2025, and the ex-dividend date and cash dividend payment date is September 25. The tax deduction policies for different types of shareholders vary; individual shareholders holding shares for more than 1 year are temporarily exempt from personal income tax, while QFIIs are taxed at 10%

    Zhitong·
    SH
    600161
    +0.59%
    Zhitong·
    SH
    600161
    +0.59%
    © 2025 Longbridge｜Disclaimer